Antidepressant Drugs: MAOIs and Other Agents

MAOIs inhibit monoamine oxidase, an enzyme that breaks down neurotransmitters like serotonin, dopamine, and norepinephrine. By blocking this enzyme, MAOIs increase neurotransmitter levels in the brain, enhancing mood regulation. They are typically reserved as last-line agents for patients unresponsive or intolerant to other antidepressant treatments due to dietary restrictions and drug interactions.

Bupropion weakly inhibits dopamine and norepinephrine reuptake, distinguishing it from serotonin-focused agents. This mechanism makes it particularly useful for treating depression while aiding smoking cessation. Unlike many antidepressants, bupropion carries a low risk of sexual dysfunction, making it a preferred option for patients concerned about this side effect.

Mirtazapine acts as a central presynaptic alpha-2 sympatholytic, enhancing serotonin and norepinephrine neurotransmission. Its sedating properties make it effective for treating major depressive disorder, particularly in patients with insomnia or poor appetite. However, sedation and weight gain are common adverse effects that limit its use in some patients.

Vortioxetine uses a multi-modal approach by inhibiting serotonin reuptake while agonizing 5-HT1a receptors and antagonizing 5-HT3 and 5-HT7 receptors. This versatile mechanism makes it effective for managing major depressive disorder, particularly in patients with cognitive symptoms or inadequate response to other treatments. Common side effects include nausea, constipation, and sexual dysfunction.

Both nefazodone and trazodone act as weak serotonin reuptake inhibitors with sedating properties. Nefazodone is primarily used for major depressive disorder, while trazodone is commonly prescribed for treating insomnia. Their sedative effects make them useful for patients with depression accompanied by sleep disturbances, though they are less potent than antidepressant drugs tricyclics SSRIs and SNRIs.

MAOIs carry significant adverse effects including hypertensive crisis from tyramine-containing foods, drowsiness, orthostatic hypotension, blurred vision, dry mouth, and constipation. These risks, combined with numerous drug interactions, necessitate strict dietary restrictions and careful medication management. Patients must avoid foods high in tyramine and inform healthcare providers of all medications before starting MAOI therapy.

Vilazodone acts as both a serotonin reuptake inhibitor and a partial 5-HT1a receptor agonist, combining mechanisms to enhance serotonin neurotransmission. This dual action contributes to its antidepressant efficacy while maintaining an adverse effect profile similar to SSRIs. It is used to treat major depressive disorder in patients seeking alternative mechanisms to standard serotonin-focused agents.